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Helicobacter pylori is a microaerophilic, spiral-shaped and gram-negative microorganism that 
produces various virulence factors such as CagA, VacA, urease, and host cells adhesins, which 
in a synchronous concert, allow H. pylori to colonize and infect the host gastric epithelium. 
H. pylori infection is associated with some severe side effects in human, such as gastritis, peptic 
ulcer, non-Hodgkin’s lymphoma and adenocarcinoma. CagA is the most notorious virulence factor 
of H. pylori. It is known as the first bacterial oncoprotein. The gene encoding CagA is localized 
on the cag pathogenicity island (cagPAI), a 40kbp DNA segment which also carries genes for the 
type four secretion system (T4SS) of H. pylori. The interaction of CagA with intracellular partner 
proteins leads to some irreversible alteration of host cells by increasing cell size, elevating motility, 
phenomena known as the “hummingbird phenotype”. CagA also disrupts the epithelium apical 
junctions and thereby destroys the normal epithelial architecture. A tyrosine phosphorylation 
site, named EPIYA motif, helps CagA to bind to cytosolic proteins in a phosphorylation-dependent 
manner. CagA is also interacts with host proteins in a phosphorylation-independent fashion, which 
altogether will assist to develop adenocarcinoma in infected cells. This review summarizes the core 
data on the structure and function of CagA and its role in conferring the main pathophysiologic 
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effects of H. pylori infection as well as suggesting a therapeutic option for treatment of H. pylori 
infection based on CagA virulence.
Keywords: adenocarcinoma, cagPAI, EPIYA, T4SS, hummingbird phenotype.
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Helicobacter pylori – это микроаэрофильная, спиралевидная, грамотрицательная бактерия, 
которая производит различные факторы вирулентности, такие как CagA, VacA, уреаза, а 
также адгезины, которые обеспечивают адгезию к клетке-хозяину. Синхронизированное 
взаимодействие факторов вирулентности позволяет H. pylori колонизировать и инфицировать 
эпителий желудка хозяина. Инфицирование организма человека H. pylori вызывает ряд 
побочных эффектов, таких как гастрит, язвенная болезнь желудка и двенадцатиперстной 
кишки, неходжкинская лимфома и аденокарцинома. CagA является наиболее печально 
известным фактором вирулентности H. pylori и признан первым бактериальным онкогеном. 
Он расположен на островке патогенности cag (cagPAI) – сегменте ДНК размером 40 т.п.н., 
который также содержит гены системы секреции четвертого типа (T4SS) H. pylori. 
Взаимодействие CagA с внутриклеточными белками-партнерами приводит к некоторым 
необратимым изменениям в клетках хозяина (увеличение их размера, повышение подвижности 
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клеток), а также возникновению в клетках феномена, известного под названием «фенотип 
колибри». CagA также разрушает соединения в апикальном полюсе эпителиальных клеток, 
и тем самым разрушает нормальную архитектуру эпителия. Сайт фосфорилирования 
тирозина, называемый EPIYA мотивы, помогает CagA связываться с цитозольными белками 
фосфорилированно-зависимым образом. Также CagA может взаимодействовать с белками 
хозяина фосфорилированно-независимым способом, что в совокупности способствует 
развитию аденокарциномы в инфицированных клетках. В данном обзоре обобщены основные 
данные о структуре и функциях CagA, его роли в развитии основных патофизиологических 
эффектов в результате инфицирования H. pylori, а также о терапевтическом варианте 
лечения инфекции, вызываемой H. pylori, содержащей CagA фактор вирулентности.
Ключевые слова: аденокарцинома, cagPAI, EPIYA, T4SS, фенотип колибри.
Introduction
Since the discovery of a spiral bacterium 
named Helicobacter pylori in 1982 by Marshall 
and Warren (Marshall and Warren, 1984), a 
significant amount of attention is given to this 
pathogen of various human gastric diseases. 
H. pylori is a microaerophilic and gram-negative 
microorganism which colonizes the mucosal layer 
of gastric tissue (Tohidpour, 2016). Two original 
morphological shapes, bacillary and coccoid, 
have been described for H. pylori. Although the 
bacillary form is clearly the predominant form, 
the coccoid morphology is the only form of 
H. pylori observed in vivo. It is thought that the 
bacillary form is virulent and the coccoid form 
mainly serves to protect the microorganism. 
The bacillary form of H. pylori is highly motile 
with multiple unipolar flagella (Chan et al., 1994; 
Covacci et al., 1999).
H. pylori has successfully colonized the 
stomach of around 50% of the world population. 
However, the prevalence of its infection varies 
within and between countries. The rate of infection 
depends on the socioeconomic levels as well as 
the genetic background and lifestyle of the hosts 
that are affected. In such regions as the East Asia 
and some parts of Latin America, the prevalence 
of infection tends to be high. In these areas, the 
initial encounter with the bacteria usually occurs 
in childhood, so that about 80% of the adult 
population will develop the infection by the age of 
about 20. In contrast, developed countries such as 
Europe, USA, or Australia, show less prevalence 
of H. pylori infection in children (aged below 10) 
and adults show a maximum 40% rate of infection 
(aged 30 to 40) (Konturek et al., 2005; Eusebi et 
al., 2014; Crew and Neugut, 2006; Graham et 
al., 1991; Yamamoto, 2001). In 1955, the overall 
prevalence of H. pylori infection in children in 
St. Petersburg, Russia, was 44%. Ten years later 
this rate decreased to 13%, probably due to the 
significant improvement of household hygienic 
practices and use of anti-H. pylori eradication 
therapies. In fact, several studies showed that the 
rate of H. pylori infection is significantly higher 
in rural areas compared to the urban sites, which 
further approves the effect of lifestyle on the 
disease incidence by H. pylori (Malaty, 2007; 
Tkachenko et al., 2007; Dore et al., 2002).
H. pylori produces many enzymes that 
facilitate colonization; such as catalase, 
phospholipase, thioredoxin reductase, and 
urease. Urease is a hydrolysis enzyme, which 
breaks the urea into ammonium and carbon 
dioxide and therefore provides an ammonia foam 
which protects the bacteria from the harsh acidic 
environment of the stomach (Chan et al., 1994; 
Covacci et al., 1999; Cover and Blaser, 1992; 
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Weeks et al., 2000; Windle et al., 2000). The 
bacterium usually enters the stomach through the 
fecal-oral route, but it can also contaminate food 
or water. However, the person-to-person contact, 
especially within the families is known as the 
primary source of contamination (Nurgalieva et 
al., 2002; Klein et al., 1991; Hopkins et al., 1993). 
H. pylori has a colonization site specificity to 
the gastric epithelium and uses its polar flagella 
to actively attach to the epithelium and resist the 
gastric flow which normally removes the hostile 
pathogens from the gastric lumen. H. pylori 
then migrates to the surface of epithelium, the 
pyloric antrum, which has a higher pH (6-7) and 
is optimal for the growth and colonization of 
H. pylori strains (Eaton et al., 1989; Scott et al., 
1998).
Major virulence factors  
of H. pylori
Adaptation of H. pylori to survive in the 
acidic niche of gastric epithelium has enabled 
it to induce severe pathological outcomes such 
as gastritis, peptic ulcer, and gastric cancer. 
H. pylori can produce various virulence factors, 
which help to colonize the stomach tissue and 
damage the epithelial mucosa such as cytotoxin-
associated gene A antigen (CagA), vacuolating 
toxin (VacA), Urease, blood group antigen-
binding adhesin (BabA), outer inflammatory 
protein (OipA), and induced by contact with 
epithelium protein (IceA).
Cytotoxin associated gene A  
antigen (CagA)
CagA is the most important virulence factor 
of H. pylori with a well-established role in the 
induction of mucosal inflammation. It is a 120-
145 kDa protein secreted by the virulent strains of 
H. pylori. CagA function is associated with some 
of the most notorious pathophysiologic outcomes 
of H. pylori infection. The gene encoding CagA 
is located at one end of a large 40 kbp DNA 
segment called cag Pathogenicity Island (cagPAI). 
It is assumed that cagPAI has been inherited by 
H. pylori from unknown ancestors through the 
horizontal gene transfer mechanism. The cagPAI 
comprises about 27-31 genes, which mainly 
encode CagA and subunits (18 genes) of the type 
IV secretion system (TFSS) of H. pylori (which 
upon assembly, form a tunneling apparatus for 
delivery of CagA into the host cells) (Covacci et 
al., 1993). Based on the ability to produce CagA, 
the strains of H. pylori are divided into two 
subpopulations: cagA-positive and cagA-negative. 
The cagA-positive H. pylori strains are associated 
with a higher degree of gastric inflammation and 
are more virulent than the cagA-negative strains 
(Kuipers et al., 1995; Parsonnet et al., 1997).
Interaction of CagA  
with host proteins  
and development of adenocarcinoma
Upon translocation into the host cytoplasm 
using the TFSS, CagA localizes itself to the 
inner leaflet of the plasma membrane and 
undergoes tyrosine phosphorylation by several 
intracellular kinases such as c-Src, Fyn, and Lyn 
(Selbach et al., 2002; Stein et al., 2002). Tyrosine 
phosphorylation of cytosolic proteins plays a 
crucial role in transmitting intracellular signals 
for growth, movement or differentiation in the 
mammalian cell. Studies showed that tyrosine 
phosphorylation of some bacterial proteins 
enables them to intervene the intracellular signal 
transduction and induce cellular dysfunction 
which can lead to cell transformation and 
malignancy (Hatakeyama and Higashi, 
2005). The tyrosine phosphorylation site of 
CagA consists of a unique conserved array of 
amino acids: Gly-Pro-Ile-Tyr-Ala, so-called 
EPIYA motif. Based on the flanking amino 
acid sequences surrounding the EPIYA, four 
different types of EPIYA segments (EPIYA: -A, 
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-B, -C, and -D), are found. EPIYA-A (32 amino 
acids (a.a)) and EPIYA B (40 a.a) are commonly 
found in all types of CagA. EPIYA-C (34 a.a) 
is mainly found in strains isolated from the 
western regions (Europe, North America, and 
Australia) and few Asian countries such as India 
and Malaysia (Western H. pylori strains). The 
number of EPIYA-C motifs on the C-terminus 
of Western-H. pylori CagA can vary up to 
maximum three. EPIYA-D, on the other hand, is 
solely found as a single repeat on the C-terminus 
of CagA in H. pylori strains isolated from the 
eastern countries such as China, South Korea, 
and Japan (East Asian H. pylori CagA) (Higashi 
et al., 2002a, 2002b; Hatakeyama, 2004; Higashi 
et al., 2005). CagA can interact with intracellular 
partner proteins in either phosphorylation-
dependent or independent fashion. In the 
phosphorylation-dependent manner, upon 
tyrosine phosphorylation, CagA interacts with 
various host cytoplasmic proteins such as 
c-terminal Src kinase (Csk), SHP-2, Grb2, CrkII, 
PI3k, and SHP-1 (Hatakeyama and Higashi, 2005; 
Higashi et al., 2002a; Hatakeyama, 2006). SHP-
2 is one the most important targets that undergo 
interaction with CagA and plays an essential 
role in signal transduction pathways of growth 
factor/cytokine receptors and regulates cellular 
responses such as proliferation, morphogenesis, 
and cell motility. Interaction of CagA with SHP-
2 disrupts its physiologic functions and leads to 
a morphologic transformation of cells, named 
the hummingbird phenotype. The CagA-SHP-2 
complex is found in the atrophic gastric mucosa 
so that the complex can play a crucial role in 
the development of atrophic gastritis and the 
transition from atrophy to intestinal metaplasia 
(Ohnishi et al., 2008; Pattis et al., 2007; 
Hatakeyama, 2006; Neel et al., 2003; Tegtmeyer 
et al., 2011).
SHP-2 has two repeated Src homology 
(SH2) domains (N-SH2 and C-SH2) on the 
N-terminal and a protein tyrosine phosphatase 
(PTP) domain on the C-terminal region. The 
N-SH2 domain of SHP-2 includes the catalytic 
cleft of the PTP domain, which blocks the 
substrate access. Interaction of CagA with the 
SH2 domains induces a conformational change 
in SHP-2, so the inhibitory effect of the PTP is 
suppressed, resulting in the activation of SHP-
2 phosphatase activity. The SHP-2 specifically 
binds to the tyrosine-phosphorylated EPIYA-C, 
and EPIYA-D sites of Western and East Asian 
H. pylori strains CagA. However, the EPIYA-D 
motif shows stronger binding affinity to SHP-
2 than EPIYA-C (Higashi et al., 2002a, 2002b; 
Hof et al., 1998; Naito et al., 2006). The CagA-
SHP-2 complex dephosphorylates the activating 
tyrosine phosphorylation sites of focal adhesion 
kinase (FAK) (Tyr396, Tyr574, and Tyr575) and 
down-regulates the FAK kinase activity (Higashi 
et al., 2002a, 2002b; Tegtmeyer et al., 2011; 
Hatakeyama, 2006; Higashi et al., 2004; Higuchi 
et al., 2004). SHP-2 activates the extracellular 
signal-regulated kinase (Erk) mitogen activated 
protein (MAP) kinase pathway by both Ras-
dependent and Ras-independent mechanisms 
(Ras are GTPses which role as molecular 
switches to regulate some intracellular signaling 
pathways). CagA-SHP-2 mediated deregulation 
of Erk kinase deregulates the normal cell cycle 
and triggers the development of hummingbird 
phenotype in infected cells (Tegtmeyer et al., 
2011; Neel et al., 2003; Tsutsumi et al., 2003).
CagA can also interact with host proteins in 
a phosphorylation-independent fashion. One of 
the most well-described proteins which interacts 
with CagA in this manner is an adaptor protein 
named Grb2 (growth factor binding receptor 
protein 2). CagA binding to Grb2 activates 
Ras and elevates the cell motility, and induces 
a scattering phenotype (Hatakeyama, 2003; 
Mimuro et al., 2002). Development of gastric 
cancer (adenocarcinoma) is a multistep process, 
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which includes deregulation of intracellular 
pathways, changing the expression rate of the 
oncogenic genes and production of inflammatory 
responses. Successful colonization with CagA-
positive strains of H. pylori and persistence of 
CagA within the host cells can eventually lead 
to irreversible changes in the host cells, causing 
anomalous signals for growth, cell motility, and 
development of abnormalities in the infected 
cells (Hatakeyama, 2006). Moreover, chronic 
infection with cagA-positive strains of H. pylori 
triggers some histopathological changes in the 
gastric mucosa which show exemplary steps of so 
called the intestinal-type gastric adenocarcinoma: 
starting from the superficial gastritis to atrophic 
gastritis, intestinal metaplasia, dysplasia 
and finally ending with the adenocarcinoma 
(Hatakeyama, 2006; Yamazaki et al., 2003; 
Correa, 1992).
Analysis of CagA crystal structure
Determining the three-dimensional 
structure of CagA has been the main burden 
to identify its effect on the host cells. Due to 
the large size, lack of significant homology to 
other prokaryotic proteins and a high degree 
of flexibility, it has been difficult to establish a 
stable structural analysis of CagA, a hydrophilic 
protein with no transmembrane sequence. The 
most hydrophilic region of the CagA includes 
some region of amino acid repeats such as 
EFKNGKNKDFSK, EPIYA and a stretch of six 
asparagine amino acids (NNNNNN), which are 
on the C-terminus of CagA (Covacci et al., 1993; 
Tsutsumi et al., 2006). Currently, there are few 
successful reports of the three-dimensional (3D) 
structure of CagA. Kaplan-Turkoz et al. (2012) 
presented a crystal structure of CagA consisting 
of four domains (D1-D4). Domain 1 (D1) (amino 
acid residues 1-270) was not in the model because 
the electron density map of the latter region was 
in low quality. Domain 2 (D2) (305-642) is the 
central domain of CagA and consists of three 
subdomains. The central part of D2 forms a so-
called SLB (single-layer β-sheet) region, which 
is known as CagA binding site to β1 integrin on 
the surface of the host cell (plays a key role in 
CagA translocation). SLB consists 11 antiparallel 
strands (β1–β5 and β8–β13) with a left-hand twist 
at β8. Next subdomain, D2` is inserted between 
strands β5 and β8 and formed by β-hairpin (β6, 
β7) and helices from α8 to α10. Third subdomain, 
D2`` , comprises three helices, α11, α12 and α13. 
D2``  stabilizes the upper part of the β-sheet and 
also looks like a hairpin structure. Domain 3 
(D3) (648-705) is a single helix (α14) that links 
D2 and D4. Domain 4 (722-822) contains four 
antiparallel helices, α15-α18, which are located at 
the carboxyl terminal of CagA (Fig. 1).
Another study by Hayashi et al. (2012) studied 
the 3D structure of the N-terminus of CagA from 
H. pylori ATCC 26695. They reported that about 
70% of CagA has a stable structure which mainly 
includes the N-terminus of the protein. The rest 
30% is mainly located on the C-terminus and is 
significantly disordered. Their crystal structure 
of the N-terminal CagA consisted three domains 
(I-III). Domain I (residues 24-221) connects with 
domain II (residues 303-644) by a disordered 
region which includes about 80 amino acids. The 
interaction between the surfaces of domains II 
and I is small which implies that domain I could 
readily dissociate from domain II and therefore 
could be highly mobile in solution. Domains II 
(residues 303-644) and III (residues 645-824) are 
connected by a long α-helix (α-19) and form an 
‘‘N-shaped’’ structure in the center of CagA. This 
region includes 13 α-helices and a large β-sheet 
structure (Hayashi et al., 2012).
Optimum strategies to manage  
the infection of H. pylori
Currently, there are several types of 
therapies to treat the H. pylori infection. Some 
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of the recommendations for the eradication 
of H. pylori were adopted in 2010 by the 
scientific society of Gastroenterologists of 
Russia (Standards for the diagnosis…, 2010) 
and the Maastricht IV (Malfertheiner et al., 
2012). Accordingly, selection of the eradication 
scheme depends on the availability of particular 
patients whose bodies respond to the medication, 
as well as the sensitivity of H. pylori strains to 
these drugs. Currently, three main antibiotics 
are widely used to treat the H. pylori infections. 
These include clarithromycin, metronidazole, 
and amoxicillin (Kim et al., 2015). The term “A 
single triple therapy” refers to an elimination 
method, which consists of administration of 
two antibiotics (usually a mix of clarithromycin 
and amoxicillin) and a proton pump inhibitor 
(Molina-Infante and Gisbert, 2014; Gisbert et 
al., 2000). Although the latter method proved 
significantly effective, due to various reasons 
such as genetic polymorphism, smoking habits, 
and bacterial resistance to antibiotics (Graham 
and Fischbach, 2010; Gasparetto et al., 2012; 
Xie and Lu, 2015) its efficacy has noticeably 
decreased. Another more efficient regimen of 
therapy is called bismuth quadruple therapy, 
which includes a combination of bismuth 
subcitrate potassium, tetracycline, and a proton 
pump inhibitor (Kim et al., 2015). The quadruple 
therapy method has been remarkably successful 
in eradicating clarithromycin-resistance cases 




Fig. 1. The general schematic structure of the N-terminal domain of CagA. A – Illustration 
of the location of the domains (D1 is shown in red, the SLB is colored pink, subdomain D2′ is in 
cyan, D2′′ is shown in blue, D3 is green, and D4 is yellow. A, B, and C represent the location of 
EPIYA motifs. The PAR1-MARK kinase binding regions (Nesic et al., 2010) are shown as 
MKI1 and MKI2). B – 3D ribbon structure of the N-terminal domain of CagA. C – A cartoon 
representation of the domains of CagA (Figure source: Kaplan-Turkoz et al., 2012, Fig. 1). 
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Kim et al., 2015). The use of clarithromycin in 
the eradication schemes is only possible in areas 
where resistance is up to 15-20%. In regions 
with clarithromycin resistance higher than 20%, 
clarithromycin is suitable for determination 
of the sensitivity of H. pylori to antibiotics 
(Malfertheiner et al., 2012).
Vaccination seems a reliable option to control 
the reduced efficacy of antimicrobial-based 
therapy and prevent the development of H. pylori-
related malignancies such as adenocarcinoma. 
The currently available anti-H. pylori vaccine 
contains recombinant CagA, VacA, and H. pylori-
NAP (neutrophil activating protein). This vaccine 
has shown a good degree of immunogenicity and 
safety during the clinical trials, however it still 
requires further analysis before receiving the 
approval for clinical use (Malfertheiner et al., 
2008). Recent studies have found some antigens 
of H. pylori for a new vaccine so-called pan-
vaccine, which comprises a set of antigens to 
protect against H. pylori strains from different 
geographic regions (Walduck et al., 2015).
The development of a successful 
anti-H. pylori vaccine is restricted due to 
several factors (Sutton and Chionh, 2013). A 
major issue is the lack of knowledge about the 
interaction of immune system against H. pylori 
infection. Most of the studies in animal models 
could only decrease the colonization rate 
of H. pylori but hardly achieved a complete 
eradication or protection against re-emergence 
of the infection. Due to the high rate of H. pylori 
infection amongst human population, an ideal 
anti-H. pylori vaccine should be able to provide 
prophylaxis and treatment simultaneously. 
What would further limit the development of a 
H. pylori vaccine is the possible benefits from 
the colonization of H. pylori to some hosts 
(Atherton and Blaser, 2009; Arnold et al., 2012). 
However, it is suggested that such advantages of 
H. pylori would be exerted in the early stages of 
the host life, while malicious effects of H. pylori 
infection start to appear over the adulthood stage 
(Atherton and Blaser, 2009). Therefore despite 
the solid knowledge that H. pylori can develop 
very adverse effects on its host, the potential of 
having some benefits in the early stages of host 
colonization shows that it is critical to carefully 
design vaccines which are based on the most 
virulent factors of H. pylori. Perhaps the best 
candidate for such vaccine strategy is CagA, 
which is only found in the pathogenic strains of 
H. pylori. Therefore, by eliminating the CagA-
positive H. pylori strains and allowing the CagA-
negative strains of H. pylori to colonize, the 
vaccination therapy would allow to reduce the 
adverse pathogenic effects but also to receive the 
advantage of commensalism between the non-
pathogenic H. pylori strains and human host. In 
other words, a valuable H. pylori vaccine would 
be able to prevent gastric cancer, even without 
providing the sterilizing immunity.
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